Quick Answer
Jasper Therapeutics, Inc. reported Diluted EPS of $3.95 per share (loss) for fiscal year 2025.
Jasper Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$3.95 | +19.2% |
| 2024 | -$4.89 | +20.9% |
| 2023 | -$6.18 | +40.2% |
| 2022 | -$10.33 | -284.0% |
| 2021 | -$2.69 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.13 | +8.9% | +35.1% |
| June 30, 2025 | -$1.74 | -79.4% | -23.4% |
| March 31, 2025 | -$1.41 | -36.9% | -13.7% |
| September 30, 2024 | -$1.24 | +73.5% | -27.8% |
| June 30, 2024 | -$0.97 | +34.0% | +5.8% |
| March 31, 2024 | -$1.03 | +36.4% | +78.0% |
| September 30, 2023 | -$4.68 | -1362.5% | -218.4% |
| June 30, 2023 | -$1.47 | -406.9% | +9.3% |
- Jasper Therapeutics, Inc. showed an increase of +19.2% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Jasper Therapeutics, Inc.’s diluted eps has declined by 46.8% (from $2.69 per share (loss) to $3.95 per share (loss)).
- The most recent figure is from Jasper Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: